NCT01146756View on ClinicalTrials.gov

MEK Inhibitor and Thoracic Radiotherapy Trial

PHASE1CompletedINTERVENTIONAL
Enrollment

21

Participants

Timeline

Start Date

June 4, 2010

Primary Completion Date

February 8, 2017

Study Completion Date

February 8, 2017

Conditions
Non Small Cell Lung Cancer
Interventions
DRUG

AZD6244

MEK inhibitor AZD6244 (Selumentinib) in combination with thoracic radiotherapy

Trial Locations (1)

M20 4BX

The Christie NHS Foundation Trust, Manchester

Sponsors

Collaborators (1)

AstraZeneca
All Listed Sponsors
collaborator

AstraZeneca

INDUSTRY

collaborator

University of Manchester

OTHER

lead

The Christie NHS Foundation Trust

OTHER